|
US73627A
(en)
*
|
|
1868-01-21 |
|
Improved paint-compound |
|
US348237A
(en)
*
|
|
1886-08-31 |
|
richards |
|
US4196265A
(en)
|
1977-06-15 |
1980-04-01 |
The Wistar Institute |
Method of producing antibodies
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4469797A
(en)
|
1982-09-23 |
1984-09-04 |
Miles Laboratories, Inc. |
Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
|
|
US4737462A
(en)
|
1982-10-19 |
1988-04-12 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
|
|
US4966843A
(en)
|
1982-11-01 |
1990-10-30 |
Cetus Corporation |
Expression of interferon genes in Chinese hamster ovary cells
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4703008A
(en)
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
|
NZ210501A
(en)
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
|
KR850004274A
(ko)
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
|
US5082658A
(en)
|
1984-01-16 |
1992-01-21 |
Genentech, Inc. |
Gamma interferon-interleukin-2 synergism
|
|
EP0158198A1
(en)
|
1984-03-29 |
1985-10-16 |
Takeda Chemical Industries, Ltd. |
DNA and use thereof
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US4667016A
(en)
|
1985-06-20 |
1987-05-19 |
Kirin-Amgen, Inc. |
Erythropoietin purification
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US5679543A
(en)
|
1985-08-29 |
1997-10-21 |
Genencor International, Inc. |
DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
|
|
US5643565A
(en)
|
1985-09-20 |
1997-07-01 |
Chiron Corporation |
Human IL-2 as a vaccine adjuvant
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US5359035A
(en)
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
|
DE3712985A1
(de)
|
1987-04-16 |
1988-11-03 |
Hoechst Ag |
Bifunktionelle proteine
|
|
EP0237019A3
(en)
|
1986-03-14 |
1988-03-09 |
Toray Industries, Inc. |
Interferon conjugate and production thereof using recombinant gene
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
DK173067B1
(da)
|
1986-06-27 |
1999-12-13 |
Univ Washington |
Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
|
|
US4894227A
(en)
|
1986-08-01 |
1990-01-16 |
Cetus Corporation |
Composition of immunotoxins with interleukin-2
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5508031A
(en)
|
1986-11-21 |
1996-04-16 |
Cetus Oncology Corporation |
Method for treating biological damage using a free-radial scavenger and interleukin-2
|
|
US4732683A
(en)
|
1986-12-02 |
1988-03-22 |
Biospectrum, Inc. |
Purification method for alpha interferon
|
|
US5019368A
(en)
|
1989-02-23 |
1991-05-28 |
Cancer Biologics, Inc. |
Detection of necrotic malignant tissue and associated therapy
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
DE3853740T2
(de)
|
1987-06-10 |
1995-11-09 |
Dana Farber Cancer Inst Inc |
Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
|
|
US5064646A
(en)
|
1988-08-02 |
1991-11-12 |
The University Of Maryland |
Novel infectious bursal disease virus
|
|
DE3880766D1
(de)
|
1987-09-02 |
1993-06-09 |
Ciba Geigy Ag |
Konjugate von interferon alpha mit immunglobulinen.
|
|
DE3850542T2
(de)
|
1987-09-23 |
1994-11-24 |
Bristol Myers Squibb Co |
Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
|
|
PT88641B
(pt)
|
1987-10-02 |
1993-04-30 |
Genentech Inc |
Metodo para a preparacao de uma variante de adesao
|
|
ZA888978B
(en)
|
1987-12-04 |
1990-07-25 |
Du Pont |
Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
CA1341588C
(en)
|
1988-01-26 |
2009-01-06 |
Michel Revel |
Human ifn-beta2/i1-6, its purification and use
|
|
US5120525A
(en)
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
|
US4975369A
(en)
|
1988-04-21 |
1990-12-04 |
Eli Lilly And Company |
Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|
|
IT1217724B
(it)
|
1988-05-26 |
1990-03-30 |
Ist Naz Ric Sul Cancro |
Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
|
|
IE62463B1
(en)
|
1988-07-07 |
1995-02-08 |
Res Dev Foundation |
Immunoconjugates for cancer diagnosis and therapy
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US5457038A
(en)
|
1988-11-10 |
1995-10-10 |
Genetics Institute, Inc. |
Natural killer stimulatory factor
|
|
US5242824A
(en)
|
1988-12-22 |
1993-09-07 |
Oncogen |
Monoclonal antibody to human carcinomas
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
ZA902949B
(en)
|
1989-05-05 |
1992-02-26 |
Res Dev Foundation |
A novel antibody delivery system for biological response modifiers
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
DE69019609T2
(de)
|
1989-07-07 |
1995-11-30 |
Takeda Chemical Industries Ltd |
Proteine und deren Herstellung.
|
|
US5073627A
(en)
|
1989-08-22 |
1991-12-17 |
Immunex Corporation |
Fusion proteins comprising GM-CSF and IL-3
|
|
KR100221066B1
(ko)
|
1989-10-13 |
1999-10-01 |
스튜어트 엘.왓트 |
에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
|
|
US5856298A
(en)
|
1989-10-13 |
1999-01-05 |
Amgen Inc. |
Erythropoietin isoforms
|
|
DE69034247T2
(de)
|
1989-12-22 |
2008-04-17 |
F. Hoffmann-La Roche Ag |
Zytotoxischer Lymphozyten-Reifefaktor 40kD Untereinheit und monoklonale Antikörper spezifisch dafür
|
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
US7253264B1
(en)
|
1990-06-28 |
2007-08-07 |
Sanofi-Arentideutschland GmbH |
Immunoglobulin fusion proteins, their production and use
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
US5709859A
(en)
|
1991-01-24 |
1998-01-20 |
Bristol-Myers Squibb Company |
Mixed specificity fusion proteins
|
|
US6072039A
(en)
|
1991-04-19 |
2000-06-06 |
Rohm And Haas Company |
Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
WO1993005169A1
(en)
|
1991-08-30 |
1993-03-18 |
Fred Hutchinson Cancer Research Center |
Hybrid cytokines
|
|
US20020037558A1
(en)
*
|
1991-10-23 |
2002-03-28 |
Kin-Ming Lo |
E.coli produced immunoglobulin constructs
|
|
US6627615B1
(en)
*
|
1991-12-17 |
2003-09-30 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
|
JP3649335B2
(ja)
|
1992-04-01 |
2005-05-18 |
ザ ロックフェラー ユニバーシティー |
樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
|
|
ATE311895T1
(de)
|
1992-05-26 |
2005-12-15 |
Immunex Corp |
Neue zytokine die cd30 binden
|
|
EP0646178A1
(en)
|
1992-06-04 |
1995-04-05 |
The Regents Of The University Of California |
expression cassette with regularoty regions functional in the mammmlian host
|
|
US5614184A
(en)
|
1992-07-28 |
1997-03-25 |
New England Deaconess Hospital |
Recombinant human erythropoietin mutants and therapeutic methods employing them
|
|
DE69332485T2
(de)
|
1992-08-11 |
2003-11-13 |
The President And Fellows Of Harvard College, Cambridge |
Immunmodulierende peptide
|
|
DE4228839A1
(de)
|
1992-08-29 |
1994-03-03 |
Behringwerke Ag |
Verfahren zum Nachweis und zur Bestimmung von Mediatoren
|
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
CA2126967A1
(en)
|
1992-11-04 |
1994-05-11 |
Anna M. Wu |
Novel antibody construct
|
|
ATE342356T1
(de)
|
1992-11-05 |
2006-11-15 |
Sloan Kettering Inst Cancer |
Prostata-spezifisches membranantigen
|
|
US5738849A
(en)
|
1992-11-24 |
1998-04-14 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
|
|
US5543297A
(en)
|
1992-12-22 |
1996-08-06 |
Merck Frosst Canada, Inc. |
Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
|
|
US6096331A
(en)
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US5738852A
(en)
|
1993-04-20 |
1998-04-14 |
Solis Therapeutics, Inc. |
Methods of enhancing antigen-specific T cell responses
|
|
US5759551A
(en)
|
1993-04-27 |
1998-06-02 |
United Biomedical, Inc. |
Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
|
|
AU697453B2
(en)
|
1993-04-29 |
1998-10-08 |
Abbott Laboratories |
Erythropoietin analog compositions and methods
|
|
US5554512A
(en)
|
1993-05-24 |
1996-09-10 |
Immunex Corporation |
Ligands for flt3 receptors
|
|
CA2125763C
(en)
|
1993-07-02 |
2007-08-28 |
Maurice Kent Gately |
P40 homodimer of interleukin-12
|
|
IL192290A0
(en)
|
1993-08-17 |
2008-12-29 |
Kirin Amgen Inc |
Erythropoietin analogs
|
|
US5639725A
(en)
|
1994-04-26 |
1997-06-17 |
Children's Hospital Medical Center Corp. |
Angiostatin protein
|
|
ATE355379T1
(de)
|
1994-04-26 |
2006-03-15 |
Childrens Medical Center |
Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
|
|
US5837682A
(en)
|
1996-03-08 |
1998-11-17 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
|
CU22615A1
(es)
|
1994-06-30 |
2000-02-10 |
Centro Inmunologia Molecular |
Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
|
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
|
US5888773A
(en)
|
1994-08-17 |
1999-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of producing single-chain Fv molecules
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
EP0706799B1
(en)
|
1994-09-16 |
2001-11-14 |
MERCK PATENT GmbH |
Immunoconjugates II
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5691309A
(en)
|
1995-01-31 |
1997-11-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5552524A
(en)
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US5891680A
(en)
|
1995-02-08 |
1999-04-06 |
Whitehead Institute For Biomedical Research |
Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
|
|
AU712585B2
(en)
|
1995-03-10 |
1999-11-11 |
Genentech Inc. |
Receptor activation by gas6
|
|
US5719266A
(en)
|
1995-03-17 |
1998-02-17 |
Eli Lilly And Company |
Anti-obesity proteins
|
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
|
IL122718A0
(en)
|
1995-06-30 |
1998-08-16 |
Lilly Co Eli |
Methods for treating diabetes
|
|
US6406689B1
(en)
|
1995-10-03 |
2002-06-18 |
Frank W. Falkenberg |
Compositions and methods for treatment of tumors and metastatic diseases
|
|
US5854205A
(en)
|
1995-10-23 |
1998-12-29 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic compositions and methods
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
US6080409A
(en)
|
1995-12-28 |
2000-06-27 |
Dendreon Corporation |
Immunostimulatory method
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
CA2205757C
(en)
|
1996-05-30 |
2006-01-24 |
F. Hoffmann-La Roche Ag |
Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
|
|
US5922685A
(en)
|
1996-06-05 |
1999-07-13 |
Powderject Vaccines, Inc. |
IL-12 gene therapy of tumors
|
|
ES2176574T3
(es)
*
|
1996-09-03 |
2002-12-01 |
Gsf Forschungszentrum Umwelt |
Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
|
|
US5994104A
(en)
|
1996-11-08 |
1999-11-30 |
Royal Free Hospital School Of Medicine |
Interleukin-12 fusion protein
|
|
US6100387A
(en)
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
PT973550E
(pt)
|
1997-04-11 |
2003-01-31 |
Searle & Co |
Anticorpos antagonistas anti-integrina avb3
|
|
US7227002B1
(en)
*
|
1997-04-14 |
2007-06-05 |
Micromet Ag |
Human antibodies that bind human 17-A1/EpCAM tumor antigen
|
|
US5873423A
(en)
*
|
1997-07-31 |
1999-02-23 |
Briese Industrial Technologies, Inc. |
Frustum cutting bit arrangement
|
|
AU763719B2
(en)
|
1997-12-08 |
2003-07-31 |
Merck Patent Gmbh |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
|
US20030105294A1
(en)
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
AU758860B2
(en)
*
|
1998-04-15 |
2003-04-03 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
|
RU2217168C2
(ru)
|
1998-04-17 |
2003-11-27 |
Лексиген Фармасьютикэлс Корпорейшн |
Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина
|
|
WO1999054484A1
(en)
|
1998-04-20 |
1999-10-28 |
The Regents Of The University Of California |
Modified immunoglobulin molecules and methods for use thereof
|
|
CA2328490A1
(en)
|
1998-05-14 |
1999-11-18 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fused protein
|
|
US6620382B1
(en)
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
|
AU770555B2
(en)
|
1998-08-17 |
2004-02-26 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
CA2339331C
(en)
*
|
1998-08-25 |
2011-03-01 |
Lexigen Pharmaceuticals Corporation |
Expression and export of angiogenesis inhibitors as immunofusins
|
|
US6646113B1
(en)
*
|
1998-09-17 |
2003-11-11 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
|
|
US6335176B1
(en)
|
1998-10-16 |
2002-01-01 |
Pharmacopeia, Inc. |
Incorporation of phosphorylation sites
|
|
CN1341121A
(zh)
*
|
1999-01-07 |
2002-03-20 |
利思进药品公司 |
作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
|
|
KR100922809B1
(ko)
|
1999-05-06 |
2009-10-21 |
웨이크 포리스트 유니버시티 |
면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
|
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
|
BR0010725A
(pt)
|
1999-05-19 |
2002-02-19 |
Lexigen Pharm Corp |
Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
|
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US6617135B1
(en)
*
|
1999-08-09 |
2003-09-09 |
Emd Lexigen Research Center Corp. |
Multiple cytokine protein complexes
|
|
US20050202538A1
(en)
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
WO2001036489A2
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
CA2399866C
(en)
|
2000-02-24 |
2011-05-10 |
Philogen S.R.L. |
Compositions and methods for treatment of angiogenesis in pathological lesions
|
|
US6586398B1
(en)
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
|
MXPA02011016A
(es)
|
2000-05-12 |
2004-03-16 |
Neose Technologies Inc |
Glicopeptidos recombinantes de glucolisacion in vitro.
|
|
EP1294401B1
(en)
|
2000-06-29 |
2007-08-01 |
EMD Lexigen Research Center Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
HUP0401300A3
(en)
*
|
2001-01-18 |
2005-06-28 |
Merck Patent Gmbh |
Bifunctional fusion proteins with glucocerebrosidase activity
|
|
MXPA03007316A
(es)
*
|
2001-02-19 |
2003-12-04 |
Merck Patent Gmbh |
Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
|
|
CN100522242C
(zh)
*
|
2001-02-19 |
2009-08-05 |
默克专利有限公司 |
具有降低的免疫原性的人工蛋白质
|
|
ES2393733T3
(es)
|
2001-03-07 |
2012-12-27 |
Merck Patent Gmbh |
Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
MXPA03009924A
(es)
*
|
2001-05-03 |
2004-01-29 |
Merck Patent Gmbh |
Anticuerpo recombinante especifico de tumor y uso del mismo.
|
|
TW544602B
(en)
*
|
2001-08-08 |
2003-08-01 |
Hon Hai Prec Ind Co Ltd |
Delivery notification system
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
ES2346205T3
(es)
|
2002-12-17 |
2010-10-13 |
Merck Patent Gmbh |
Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
|
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
WO2005063820A2
(en)
|
2003-12-30 |
2005-07-14 |
Merck Patent Gmbh |
Il-7 fusion proteins
|
|
DK1699821T3
(da)
|
2003-12-31 |
2012-07-16 |
Merck Patent Gmbh |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
|
|
DE602005016773D1
(de)
|
2004-01-22 |
2009-11-05 |
Merck Patent Gmbh |
Antikrebs-antikörper mit reduzierter komplementfixierung
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
ES2342964T3
(es)
|
2004-12-09 |
2010-07-20 |
Merck Patent Gmbh |
Variantes de la interleucina-7 con inmunogenicidad reducida.
|
|
US20070104689A1
(en)
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
DK2270050T3
(da)
|
2005-12-30 |
2013-08-12 |
Merck Patent Gmbh |
Anti-CD19-antistoffer med nedsat immunogenicitet
|
|
AU2006332138B2
(en)
|
2005-12-30 |
2012-03-22 |
Merck Patent Gmbh |
Interleukin-12p40 variants with improved stability
|
|
PT1966244E
(pt)
|
2005-12-30 |
2012-05-17 |
Merck Patent Gmbh |
Anticorpos anti-il-6 impedindo a ligação da il-6 complexada com il-6ralfa a gp130
|
|
AR060070A1
(es)
|
2006-03-24 |
2008-05-21 |
Merck Patent Gmbh |
Dominios proteicos heterodimericos obtenidos por ingenieria
|
|
WO2008003473A2
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|